3653 results for «234»
3653 results
First-in-human studies in cardiovascular devices: from first 10 patients to global innovation — How efficient early studies advance emerging technologies
20 May 2026 – From EuroPCR 2026
Understand the pivotal role of first-in-human studies in advancing cardiovascular device innovation through operational insights from early patient experiences. This session reviews cutting-edge technologies including percutaneous left ventricular assist devices, transcatheter leaflet augmentation, physiology-guided PCI, synchronized diaphragmatic stimulation, pulmonary artery denervation, and perspectives on translating early...
Innovation in transcatheter mitral valve interventions
21 May 2026 – From EuroPCR 2026
This comprehensive session presents the latest innovations in transcatheter mitral valve interventions, highlighting cutting-edge devices and clinical experiences. Topics include early feasibility studies of novel hemivalve systems, first-in-human experiences with new mitral valve replacement technologies, advances in transcatheter edge-to-edge repair (TEER) with one-year outcome data, and...
Routine primary PCI: what can go wrong?
21 May 2026 – From EuroPCR 2026
This session offers an in-depth examination of potential complications during routine primary PCI, focusing on prevention and management strategies. Key learning points include understanding no-reflow phenomena, managing STEMI in post-CABG patients, and handling thrombus burden effectively. Real-world cases illustrate decision-making processes and therapeutic approaches to optimize...
Mitral paravalvular leak closure: case-bases strategies
20 May 2026 – From EuroPCR 2026
This session presents case-based strategies for mitral paravalvular leak closure, highlighting complex percutaneous approaches including multivalvular failure management, apical access techniques, and transatrial direct surgical valve-in-MAC procedures. It features challenging clinical scenarios demonstrating innovative solutions for hemolytic leaks and complex paravalvular defects.
Insight from recent evidence in coronary artery disease: value of DCB for de novo lesions (SELUTION) and imaging for left main PCI (OPTIMAL)
21 May 2026 – From EuroPCR 2026
This session reviews pivotal recent evidence impacting daily practice in coronary artery disease management. It discusses the role of drug-coated balloons (DCB) for de novo lesions as evaluated in the SELUTION trial and evaluates intracoronary imaging strategies for left main PCI as presented in the OPTIMAL...
The structural bailout playbook: managing complications
21 May 2026 – From EuroPCR 2026
The session presents a practical structural bailout playbook focused on managing complex complications during structural heart interventions. It features challenging cases such as unusual atrial septal defect closure complications, navigation of a displaced patent ductus arteriosus stent in infants, percutaneous closure of mitral paravalvular leaks with...
Revascularisation in patients with multivessel disease and severe left ventricular impairment
21 May 2026 – From EuroPCR 2026
This session focuses on revascularisation strategies for patients with multivessel coronary disease complicated by severe left ventricular impairment. It emphasizes patient selection criteria, the crucial role of the heart team in decision-making, and optimization of percutaneous revascularisation outcomes. The content includes comprehensive case presentations and discussions...
Advanced heart failure: left ventricular assist device as bridge to optimise guided-directed medical therapy
21 May 2026 – From EuroPCR 2026
This session explores advanced heart failure management with a focus on guided-directed medical therapy and the role of left ventricular assist devices (LVAD) as a bridge to therapy optimization. It discusses clinical, imaging, and biological parameters indicating LVAD use and highlights devices such as the Impella...
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
First-in-human experience with EasyCross: a novel catheter for a safe and correct aortic valve crossing
14 Jun 2024
This EIJ image highlights a new device designed to enhance the safety and efficiency of ViV TAVI procedures, particularly TAV-in-TAV, by reducing attempts to cross the valve and preventing guidewire misnavigation, thereby minimizing complications and procedure time.
Rapid CT-guided emergency TAVI-in-TAVI-in-valve for cardiogenic shock with high coronary obstruction risk
14 Apr 2026
An 85-year-old man presented in cardiogenic shock with torrential aortic regurgitation after prior surgical and TAVI valve-in-valve procedures. With high coronary obstruction risk, urgent CT assessment and in-silico simulations guided a rapid redo TAVI-in-TAVI-in-valve implantation, demonstrating that CT-assisted emergency redo-TAVI is feasible and lifesaving in high-risk...
Siemens Healthineers introduces industry-first seamlessly integrated end-to-end solution for CT-guided percutaneous coronary interventions
19 May 2026
UNIVERSAL: routine ultrasonography guidance for femoral vascular access for cardiac procedures - A randomized clinical Trial
19 Sep 2022
Ali Nazmi Calik provides his take on UNIVERSAL randomized clinical trial, which questioned whether routine ultrasonography guidance for CFA access for cardiac procedures reduces bleeding or vascular complications. This trial was presented by Sanjit S. Jolly during TCT 2022.
Author
